Zura Bio Limited Stock Market Outlook
| ZURA Stock | 5.18 -0.14 -2.63% |
This sentiment measure is descriptive rather than personalized advice and should be used with other evidence before acting on it. Around 62% of recent sentiment around Zura Bio has leaned defensive over the recent sample. Taken on its own, that leaves the current sentiment reading for Zura Bio Limited below neutral at this time.
Investor Comfort Level
Alarmed
39
PanicConfidence
Elasticity to Hype and News Sentiment
Tracking Zura Bio Limited mixed news sentiment (50%) is particularly informative when headlines and price behavior start diverging. That reading becomes more actionable when paired with valuation context and recent technical trend direction.
Given a 90-day horizon, with maximum risk tolerance, the model output for Zura Bio Limited is 'Strong Buy'. Our automated recommendation for Zura Bio is built from quantitative evidence and fundamental indicators. The analysis combines quantitative signals with investor-specific risk parameters. The recommendation evaluates return potential against downside risk within defined investment parameters. Complementing automated signals with independent research strengthens the broad analytical foundation.
Zura Bio |
Run Zura Bio Outlook Model
Our Zura Bio outlook engine provides a data-driven supplement to the analyst consensus on Zura Bio Limited. Macroaxis has no vested interest in Zura Bio Limited or any other instrument analyzed here. Multiple quantitative inputs drive the Zura Bio's signal across different market conditions. Combining algorithmic signals with independent analysis supports more informed decisions.
How This Model Works
The recommendation output for Zura Bio is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am willing to tolerate any risk
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Strong Buy
Market Performance | Weak | Details | |
Volatility | Elevated | Details | |
Current Valuation | Above Model Estimate | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Zura Bio's current outlook reflects mixed signals, where recent market performance has undercut momentum, while contained volatility and intact fundamental quality provide partial offset. The model's 'Strong Buy' signal reflects this balance across quantitative inputs rather than a directional bias. Over the selected time horizon, Zura Bio shows Risk Adjusted Performance of -0.03, Jensen Alpha of -0.15, and Total Risk Alpha of -0.12, which collectively support the constructive outlook.The quantitative analytical reading for Zura Bio blends historical performance patterns with current market conditions and the analyst and expert consensus to frame the risk-reward profile. For additional context on this small-cap stock, review the full set of Zura Bio reported fundamentals, including the relationship between the trailing beta and working capital ttm. Zura Bio Limited reports a shares owned by institutions of 56.48 %. Its market performance and financial distress probability provide additional context.
Recent Events and Market Context
The events below reflect recent headlines associated with Zura Bio. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Returns Distribution Density
Plotting Zura Bio's daily returns in a distribution reveals the day-to-day behavior of Zura Bio. It shows how returns are grouped around the average and how often large swings occur. Value At Risk and Upside Potential quantify both the risk and the reward. Value At Risk shows the worst-case boundary and Upside Potential shows the best-case boundary.
| Mean Return | -0.16 | Value At Risk | -6.99 | Potential Upside | 6.00 | Standard Deviation | 3.86 |
Return Density |
| Distribution |
Risk management for Zura Bio depends on quantifying the frequency and magnitude of extreme moves. The distribution chart below makes that clear for Zura Bio. Portfolio managers weigh the trade-offs across risk-return profiles. Return distribution analysis highlights the frequency and magnitude of extreme price moves in Zura Bio.
Key Drivers of Volatility and Market Exposure
Market risk ties Zura Bio to macro cycles, whereas company or sector-specific developments represent independent drivers. Volatility metrics help measure this balance. Zura Bio Limited (ZURA) recorded a Mean Deviation of 3.03 and a Standard Deviation of 3.86.
α | Alpha over Dow Jones | -0.1542 | |
β | Beta against Dow Jones | 1.47 | |
σ | Overall volatility | 3.82 | |
Ir | Information ratio | -0.0414 |
Fundamentals Vs Peers
Zura Bio is measured here against stocks with similar revenue scale, margin profile, and capital structure. The comparison below reveals whether Zura Bio generates superior or inferior returns relative to similar stocks. Divergence between Zura Bio's valuation multiples and its peer group flags either mispricing or a structural difference in quality. Direct comparison with similar stocks converts Zura Bio's standalone financial data into an actionable relative signal.
| Better Than Average | Worse Than Average | Compare Zura Bio to competition |
| Fundamentals | Zura Bio | Peer Average |
| Return On Equity TTM | -0.52 | -0.31 |
| Return On Asset TTM | -0.32 | -0.14 |
| Current Valuation | 386.34 M | 16.62 billion |
| Shares Outstanding | 94.88 M | 571.82 million |
| Shares Owned By Insiders | 21.12 % | 10.09 % |
| Shares Owned By Institutions | 56.48 % | 39.21 % |
| Number Of Shares Shorted | 6.15 M | 4.71 million |
| Price To Book TTM | 4.88 X | 9.51 X |
| EBITDA TTM | -75.25 M | 3.9 billion |
| Net Income TTM | -68.65 M | 570.98 million |
| Total Debt TTM | 12.41 M | 5.32 billion |
| Book Value Per Share TTM | 1.38 X | 1,931 |
| Cash Flow From Operations TTM | -64.81 M | 971.22 million |
| Short Ratio TTM | 9.75 X | 4.00 X |
| Earnings Per Share | -1.08 X | 3.12 X |
| Target Price | 15.5 | N/A |
| Number Of Employees | 40 | 18,840 |
| Trailing Beta | 0.089 | -0.15 |
| Market Capitalization TTM | 504.77 M | 19.03 billion |
| Total Asset TTM | 113.95 M | 29.47 billion |
| Retained Earnings TTM | -224.55 M | 9.33 billion |
| Working Capital TTM | 99.9 M | 1.48 billion |
| Net Asset | 113.95 M | N/A |
Note: Acquisition by Nistala Kiran of 285000 shares of Zura Bio at 3.38 subject to Rule 16 b-3 [view details]
Market Momentum
Zura Bio Limited mildly bearish RSI of 43 combined with above-market-beta sensitivity (1.4685) reveals whether current momentum is driven by company-specific demand or market-wide flows. Comparing these readings with sector peers helps separate stock-specific momentum from amplified market moves.
Recommendation Framework, Assumptions & Editorial Oversight
The model output for Zura Bio reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Zura Bio include ROE of -52.49%, market cap of 504.77 million. 
Zura Bio Limited metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Editorial Board
Finance background: Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.